D.A. Davidson & CO. Takes $212,000 Position in Exelixis, Inc. $EXEL

D.A. Davidson & CO. bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 4,809 shares of the biotechnology company’s stock, valued at approximately $212,000.

Other large investors also recently made changes to their positions in the company. Belpointe Asset Management LLC bought a new position in Exelixis during the 1st quarter worth $572,000. GAMMA Investing LLC increased its stake in Exelixis by 32.2% during the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company’s stock worth $201,000 after acquiring an additional 1,328 shares during the period. Envestnet Asset Management Inc. increased its stake in Exelixis by 23.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock worth $9,159,000 after acquiring an additional 47,845 shares during the period. Fortis Capital Advisors LLC bought a new position in Exelixis during the 1st quarter worth $572,000. Finally, Intech Investment Management LLC increased its stake in Exelixis by 46.4% during the 1st quarter. Intech Investment Management LLC now owns 392,022 shares of the biotechnology company’s stock worth $14,473,000 after acquiring an additional 124,297 shares during the period. Institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Leerink Partners raised Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 target price on the stock in a report on Tuesday, October 21st. Barclays started coverage on Exelixis in a report on Wednesday, September 17th. They set an “equal weight” rating and a $40.00 target price on the stock. Wells Fargo & Company lowered their price objective on Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 21st. Stifel Nicolaus lifted their price objective on Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a research report on Tuesday, July 29th. Finally, UBS Group set a $38.00 target price on Exelixis and gave the company a “neutral” rating in a research report on Wednesday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.53.

Exelixis Trading Down 0.7%

Exelixis stock opened at $38.67 on Friday. Exelixis, Inc. has a 12 month low of $31.90 and a 12 month high of $49.62. The business’s 50 day simple moving average is $38.81 and its 200 day simple moving average is $40.23. The company has a market cap of $10.41 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.79 and a beta of 0.38.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.